Clinical trial NCT00086164: Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis
Official title: A Phase 1/2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Pilot Trial to Assess the Effect of Treatment of the Recipient Vein of a Polytetrafluoroethylene (PTFE) Vascular Access Graft With Two Concentrations of E2F Decoy as Compared to Placebo on Neointimal Hyperplasia and the Preservation of Graft Function in Patients With Chronic Renal Failure Requiring Hemodialysis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Hyperplasia
Chronic Renal Failure
Keywords: edifoligide
E2F Decoy
Chronic Renal failure
hemodialysis
AV Graft
neointimal hyperplasia
Lead sponsor: Anesiva, Inc.
Sponsor class: INDUSTRY
First posted: 2004-06-29
Sex: ALL
Minimum age (years): 18
Maximum age (years): 79
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to determine the effect of recipient vein pretreatment of edifoligide (E2F Decoy), compared to placebo, on graft/recipient vein stenosis in polytetrafluoroethylene (PTFE) vascular access grafts placed for hemodialysis at 6 months after enrollment.


Eligibility criteria: Inclusion Criteria:

* Be scheduled to undergo placement of a new straight or loop arm PTFE arteriovenous hemodialysis access graft or a Vectragraft® (Thoratec, Inc.)
* Be currently receiving chronic dialysis or be expected to begin hemodialysis within 4 weeks of placement of the index PTFE graft
* Have undergone an assessment of patency (such as venography) of central veins if any of the following conditions have occurred on the ipsilateral arm intended for graft placement: presence of collateral veins, upper extremity edema or increased size (relative to the contralateral arm), history of subclavian catheter, transvenous pacemaker, or history of trauma or surgery that may have involved the neck or chest veins
* Be \> 18 and \<80 years old
* Have a documented negative serum pregnancy test (for all women of childbearing potential)
* Be using an acceptable method of birth control if of reproductive potential and agree to continue using the birth control for at least 3 months following the graft procedure
* Have agreed to participate voluntarily and have signed and dated an IRB/EC approved, Patient Informed Consent form

Exclusion Criteria:

* Have an intended recipient vein \>6 mm or \<3 mm in diameter
* Have a history of three or more previous PTFE grafts
* Have uncorrected central vein (including the subclavian vein) stenosis
* Have markedly diminished arterial pulses in the access location (unless adequate flow has been documented by arteriography or Doppler ultrasound)
* Anticipate receipt of a renal transplant within 6 months of enrollment into this study
* Have anticipated use of the index PTFE graft \<14 days after enrollment (this does not apply to Vectragraft®)
* Have a known allergy to iodinated contrast
* Have a known hypercoagulable state (e.g., antithrombin III deficiency; antiphospholipid or anticardiolipin antibodies; Factor V Leiden; circulating lupus anticoagulant; current, active, heparin-induced thrombocytopenia; Protein C or S deficiency; or a history of recurrent deep venous thrombosis not related to AV access)
* Have been in another investigational (i.e., nonapproved) drug or device study within the previous 30 days or prior participation in another clinical study with E2F Decoy
* Have been previously enrolled in this study for an earlier access graft
* Have any comorbid, nonrenal condition that makes 6-month survival questionable (e.g., end-stage cancer, advanced heart failure)
* Have a known or suspected history of drug or alcohol abuse within the previous 6 months
* Have a known allergy to any component of the investigational product (drug or device), including latex

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: National Institute of Clinical Research, American Medical Tower
state: California
city: Hudson
country: United States
facility: Outcomes Research International, Inc.
state: Florida
city: Miami
country: United States
facility: University of Miami, School of Medicine
state: Florida
city: Tampa
country: United States
facility: Tampa General Hospital
state: Florida
city: Tampa
country: United States
facility: LifeLink Transplant Institute
state: Florida
city: Atlanta
country: United States
facility: Emory University, Renal Division
state: Georgia
city: Chicago
country: United States
facility: University Transplant
state: Illinois
city: Chicago
country: United States
facility: Stoney Island Dialysis
state: Illinois
city: Indianapolis
country: United States
facility: Methodist Hospital, Tower Surgical
state: Indiana
city: Baton Rouge
country: United States
facility: Vascular Surgery Associates
state: Louisiana
city: New Orleans
country: United States
facility: Tulane Center for Abdominal Transplant
state: Louisiana
city: Detroit
country: United States
facility: Henry Ford Hospital
state: Michigan
city: Lansing
country: United States
facility: Thoracic & Cardiovascular Healthcare Foundation
state: Michigan
city: St. Louis
country: United States
facility: St. Louis University, Division of Nephrology
state: Missouri
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
city: New York
country: United States
facility: NYU Medical Center
state: New York
city: New York
country: United States
facility: St. Luke's Hospital, Department of Surgery
state: New York
city: Rochester
country: United States
facility: University of Rochester, The Center for Vascular Disease
state: New York
city: Greenville
country: United States
facility: Surgical Education
state: South Carolina
city: Salt Lake City
country: United States
facility: University of Utah School of Medicine, Dept of Surgery
state: Utah
city: Charlottesville
country: United States
facility: Nephrology Clinical Research Center
state: Virginia
Study officials:
References: